KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Total Liabilities (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Total Liabilities for 8 consecutive years, with $237.5 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 4.38% to $237.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $237.5 million through Dec 2025, down 4.38% year-over-year, with the annual reading at $237.5 million for FY2025, 4.38% down from the prior year.
  • Total Liabilities hit $237.5 million in Q4 2025 for Vir Biotechnology, up from $223.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $886.1 million in Q1 2022 to a low of $223.4 million in Q3 2025.
  • Historically, Total Liabilities has averaged $413.5 million across 5 years, with a median of $331.4 million in 2021.
  • Biggest five-year swings in Total Liabilities: surged 400.75% in 2021 and later tumbled 64.52% in 2024.
  • Year by year, Total Liabilities stood at $522.4 million in 2021, then surged by 38.61% to $724.1 million in 2022, then plummeted by 54.59% to $328.8 million in 2023, then fell by 24.45% to $248.4 million in 2024, then decreased by 4.38% to $237.5 million in 2025.
  • Business Quant data shows Total Liabilities for VIR at $237.5 million in Q4 2025, $223.4 million in Q3 2025, and $245.1 million in Q2 2025.